Patients continue PAH drug to monitor long-term safety
NCT ID NCT02759419
Summary
This study allowed patients with pulmonary arterial hypertension (PAH) who had previously taken riociguat in Bayer clinical trials to continue receiving the medication long-term. The main goal was to monitor the drug's safety and side effects over an extended period. Only 18 patients participated, all of whom had already been taking riociguat and were expected to benefit from continuing treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Besançon, 25030, France
-
Study site
Brest, F-29609, France
-
Study site
Le Kremlin-Bicêtre, 94275, France
-
Study site
Lille, 59037, France
-
Study site
Rouen, 76031, France
-
Study site
Seoul, Seoul Teugbyeolsi, 03722, South Korea
-
Study site
Seoul, Seoul Teugbyeolsi, 05505, South Korea
-
Study site
Seoul, Seoul Teugbyeolsi, 3080, South Korea
-
Study site
Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.